• Andrew von Eschenbach, commissioner of the FDA, reported the appointment of Janet Woodcock, MD, as director of the agency's Center for Drug Evaluation and Research (CDER; Washington). Under Woodcock's leadership, the FDA launched the Critical Path Initiative designed to bridge the gap between basic scientific research and the medical product development process. Woodcock will continue to be involved in this initiative, as well as the emerging post-market surveillance collaborations with the private sector.
  • Gene Express (Toledo, Ohio) said that it has appointed James Mulshine, MD, to its Scientific Advisory Board. Mulshine is now the associate provost for research at Rush University Medical Center. Gene Express accelerates and enables drug and molecular diagnostic development by providing standardized genomic data.
  • Tim Walnofer has been named VP of sales for Spineology (St. Paul, Minnesota). Previously, Walnofer was in sales management at TranS1 and Kyphon. Spineology specializes in implant design and makes the OptiMesh deployable grafting system.
  • Paul Reitmeier has been named CEO of Time Domain (Huntsville, Alabama). Reitmeier has more than 30 years of senior management experience, having recently led three separate Siemens business units in the U.S. and in Germany since 2000. Time Domain makes ultra-wideband, real-time location systems.